• Search History (Register)
  • MeSH Browser

Welcome to the international HTA database


Showing [22721 Records] Selected Records [0 Hits] [Clear]
Year Source Title
2014     The Swedish Council on Health Technology Assessment (SBU) [Aromatase inhibitors for early-stage breast cancer]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Argon plasma coagulation for gastrointestinal lesions]
2015     The Swedish Council on Health Technology Assessment (SBU) [Arginine and caries prevention]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (Peanut allergy) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [AR101 (peanut allergy) - Addendum to Commission A21-135]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Aquapheresis – ultrafiltartion for congestive heart failure]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apremilast (Behçet’s disease) - Benefit assessment according to §35a Social Code Book V]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apremilast - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies. Systematic review of the admission criteria in acute decompensated heart failure]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies. Efficacy and safety of pharmacological treatment for bipolar disorder]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies. Development of explicit criteria for indication of admission in COPD exacerbation]
2008     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies. Development of appropriateness explicit criteria for carotid revascularization]
2009     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriateness use standards for health technologies : appropriate admission explicit criteria for heart failure (HF)]
2009     Canary Health Service [Appropriateness of the indication of physical therapy techniques]
2009     Andalusian Health Technology Assessment Area (AETSA) [Appropriateness criteria for vertebral arthrodesis]
2009     Andalusian Health Technology Assessment Area (AETSA) [Appropriate use of recombinant activated factor VII in nonhaemophilic patients]
2000     Andalusian Health Technology Assessment Area (AETSA) [Appropriate use of Factor VIII in the treatment of haemophilia. A Literature review and opinions of an expert panel on the correct use of different preparations of Factor VIII]
2005     Andalusian Health Technology Assessment Area (AETSA) [Appropriate use of Factor VIII for treatment of hemophilia - A consensus conference]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriate use of diagnostic imaging technologies in primary and secondary care : ultrasonography in breast pathology]
2010     Unidad de Evaluacion de Tecnologias Sanitarias (UETS) [Appropriate use of diagnostic imaging technologies in acute abdominal pain]
2023     Andalusian Health Technology Assessment Area (AETSA) [Appropiate indication for leadless pacemaker. Systematic review and appropriateness criteria]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Approach to personality disorders in the mental health system of the Basque Country]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Appraisal of the variability and suitability of prescribing antimicrobials in primary health care in the Basque Country]
2011     Canadian Agency for Drugs and Technologies in Health (CADTH) [Application of genetic algorithms and expert systems in medical care. Clinical applications of artificial intelligence]
2011     Andalusian Health Technology Assessment Area (AETSA) [Application of genetic algorithms and expert systems in medical care. Clinical applications of artificial intelligence]
2010     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Applicability of sentinel-lymph-node detection and biopsy in the treatment of vulval cancer]
2014     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban (extension of approval) - Benefit assessment according to §35a Social Code Book V (dossier assessment)]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2013     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apixaban - Benefit assessment according to § 35a Social Code Book V (dossier assessment)]
2010     Committee for New Health Technology Assessment (CNHTA) [APC gene,mutation[sequencing]]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Addendum to Commission A20-20]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Apalutamide (prostate cancer) - Addendum to Commission A19-09]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Aortic valve replacement with rapid deployment or sutureless valves]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anxiety disorders: does the complementary use of eye movement desensitization and reprocessing (EMDR) therapy as a psychotherapeutic approach lead to better results?]
2009     Committee for New Health Technology Assessment (CNHTA) [Antroduodenal manometry]
2021     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Antithrombotic treatments following heart valve replacement surgeries]
2011     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Antipsychotic polypharmacy in the treatment of schizophrenia]
2020     National Committee for Technology Incorporation (CONITEC) [Antimuscarinics (oxybutynin, tolterodine, solifenacin and darifenacin) for the treatment of storage dysfunction in patients with neurogenic bladder]
2015     Comite d'Evaluation et de Diffusion des Innovations Technologiques (CEDIT) [Antigermix – disinfection of endocavitary ultrasonography probes]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-eluting stents for treatment of coronary artery stenosis in patients with high risk of restenosis - rapid report]
2012     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-eluting stents for treatment of coronary artery stenosis in patients with high risk of restenosis - rapid report]
2015     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Antibody-coated drug-eluting stents for treatment of coronary artery stenosis]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Antibodies to pgp9.5 in small fiber neuropathy]
2010     Norwegian Knowledge Centre for the Health Services (NOKC) [Antibiotic therapy in hospital, oral versus intravenous treatment]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Antiangiogenic drugs in refractory age-related macular degeneration]
2009     Committee for New Health Technology Assessment (CNHTA) [Anti-saccharomyces cerevisiae antibody test]
2003     Danish Centre for Evaluation and Health Technology Assessment (DACEHTA) [Anti-immunoglobulin E (omalizumab) for the treatment of allergic asthma in adults]
2009     Committee for New Health Technology Assessment (CNHTA) [Anti-Heparin/Platelet Factor 4 antibody assey]
2010     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Anti-GD2 immunotherapy in patients with high risk neuroblastoma]
2018     Institute for Clinical Effectiveness and Health Policy (IECS) [Anti-d immunoglobulin in pregnancy and immune thrombocytopenia]
2012     Institut national d'excellence en sante et en services sociaux (INESSS) [Anti-angiogenic drugs in the treatment for age-related macular degeneration: issues associated with their use in Québec]
2022     Institute for Clinical Effectiveness and Health Policy (IECS) [Anorectal biofeedback therapy in primary constipation]
2011     Ludwig Boltzmann Institut fuer Health Technology Assessment (LBI-HTA) [Annual Report 2010. German version.]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anifrolumab (systemic lupus erythematosus) - Benefit assessment according to §35a Social Code Book V]
2022     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Anifrolumab (systemic lupus erythematosus) - Addendum to Commission A22-35]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Angiotensin II acetate (refractory hypotension in distributive shock) - Addendum to Commission A21-95]
2021     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Angiotensin II acetate (hypotension) - Benefit assessment according to §35a Social Code Book V]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Angioplasty with stent placement in patients with deep vein thrombosis]
2020     Institute for Clinical Effectiveness and Health Policy (IECS) [Angioplasty with stent placement in patients with carotid artery disease]
2023     Institute for Clinical Effectiveness and Health Policy (IECS) [Angioplasty and stenting in patients with carotid artery stenosis]
2009     Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA) [Angiographic profile of patients undergoing drug eluting stent implantation in Spain. Variability of off-label indications]
2017     Institute for Clinical Effectiveness and Health Policy (IECS) [Angiogenesis inhibitors (bevacizumab - ranibizumab) in neovascular glaucoma and corneal neovascularization]
2022     Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval (IUCPQ-ULaval) [Anesthesia information management systems]
2019     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Andexanet alfa (acute major bleeding) - Benefit assessment according to §35a Social Code Book V]
2020     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Andexanet alfa (acute major bleeding) - Addendum to Commission A19-76]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of tuberculosis isolation and prophylaxis techniques at a hospital level]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the use of simple cranium, chest and abdomen radiology in emergency hospital services]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the use of clinical protocols for monitoring the chronically ill in primary health care]
2013     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the status, systematic review and validation of a diagnostic algorithm for pulmonary thromboembolism (PTE) in the hospital emergency services of the Basque Health Service]
2000     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the scientific evidence on the effectiveness and efficiency of different kinds of hip prosthesis. Recommendations]
2005     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the evolution of main causes of mortality in 65 and older people in the Basque Country (1986-2001)]
1999     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the efficiency of the laboratory test in emergency care]
2017     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the efficacy, safety and efficiency of stabilisation of intervertebral discs using Discogel]
1998     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the efficacy of the treatments and costs of Alzheimer's disease in the Basque Country]
2020     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Analysis of the efficacy and safety of robotic spinal surgery]
2018     Agencia de Evaluacion de Tecnologias Sanitarias (AETS) [Analysis of the efficacy and safety of orthodontic-orthopedic maxillary expansion devices as an alternative to adenotonsillectomy and/or pharmacological treatment in the management of sleep apnea-hypopnea syndrome in pediatric patients]
2023     Center for Drug Evaluation (CDE) [Analysis of the effectiveness of various hemophilia treatments in Taiwan]
1996     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the cost-effectiveness of the non-mydriatic retinal camera for diabetic retinopathy]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the appropriateness of hospital admissions from emergencies]
2009     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of the adequacy of diagnostic indications of the following application techniques of cerebral MR: MR spectroscopy, diffusion, gadolinum perfusion and cerebral functional-activation MR in advanced neurological diagnosis]
2008     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of telemedicine applications in the management-coordination of specialized and primary care. Appraisal of results and costs of pre-existing experiences (teleophthalmology)]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Analysis of surgical antibiotic prophylaxis]
2008     Andalusian Health Technology Assessment Area (AETSA) [Analysis of RET mutations to perform prophylactic thyroidectomy in individuals at risk for medullary thyroid cancer]
2011     Andalusian Health Technology Assessment Area (AETSA) [Analysis of health and socioeconomic factors influencing the progressive increase in frequentation of hospital emergency services]
2011     The Swedish Council on Health Technology Assessment (SBU) [Analysis of fetal DNA in maternal blood: non-invasive fetal diagnostic tests for blood group and sex determination]
2006     Scientific Advice Unit, avalia-t; The Galician Health Knowledge Agency (ACIS) [Analysis of factors that can influence the levels of TSH in the neonatal period]
2018     Agència de Qualitat i Avaluació Sanitàries de Catalunya (AQuAS) [Analysis of diagnostic performance of transbronchial lung biopsy using cryoprobe (cryobiopsy) in the study of diffuse lung diseases]
2017     Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) [Analysis of clinical studies of medical devices]
2008     Andalusian Health Technology Assessment Area (AETSA) [Analysis of APC mutations to perform prophylactic colectomy in subjects at risk for colorectal cancer]
2015     National Evidence-based Healthcare Collaborating Agency (NECA) [Analysis for healthcare safety management system]
2001     Basque Office for Health Technology Assessment (OSTEBA) [Analysis and review of protocols and quality standards in the diagnostic process for the detection of cervical cancer]
2011     Basque Office for Health Technology Assessment (OSTEBA) [Analysis and development of preventive activities in primary care. Review of the preferential offer and its support software (PAP)]
2016     The Swedish Council on Health Technology Assessment (SBU) [Anal sphincter injuries]
2016     Basque Office for Health Technology Assessment (OSTEBA) [An image-guided system for liver surgery (CAScination)]
1998     Andalusian Health Technology Assessment Area (AETSA) [An evidence-based guideline on unstable angina management]
2015     Basque Office for Health Technology Assessment (OSTEBA) [An evaluation of the efficacy of psychosocial techniques (cognitive rehabilitation vs. psychoeducation) as an additional treatment to pharmacological treatment in bipolar disorder]
2014     Basque Office for Health Technology Assessment (OSTEBA) [An evaluation of intensity-modulated radiotherapy (IMRT)]